Aldeyra疗法
Aldeyra疗法专利
Aldeyra疗法已申请专利53。
3最受欢迎的专利主题包括:
- 眼睛的疾病和附件
- 自身免疫性疾病
- 炎症
申请日 |
授予日期 |
标题 |
相关的话题 |
状态 |
---|---|---|---|---|
4/12/2021 |
7/18/2023 |
眼和附器的自身免疫性疾病,疾病,罕见疾病,炎症,H1受体拮抗剂 |
格兰特 |
申请日 |
4/12/2021 |
---|---|
授予日期 |
7/18/2023 |
标题 |
|
相关的话题 |
眼和附器的自身免疫性疾病,疾病,罕见疾病,炎症,H1受体拮抗剂 |
状态 |
格兰特 |
最新的Aldeyra疗法新闻
2023年8月8日
今天5天8月03日变化与我分享Bragar Eagel &乡绅,pc,a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX) in the United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired Aldeyra securities between March 17, 2022 and June 20, 2023, both dates inclusive (the “Class Period”). Investors have until September 29, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit. Click here to participate in the action. Aldeyra, a biotechnology company, develops and commercializes medicnes for immune-mediated diseases. The Company is currently developing ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma cancer, proliferative vitreoretinopathy, and retinitis pimentosa, as well as rare retinal diseases characterized by inflammation and vision loss. In December 2022, Aldeyra submitted a new drug application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for ADX-2191 for the Treatment of Primary Vitreoretinal Lymphoma (the “ADX-2191 NDA”). On June 21, 2023, Aldeyra issued a press release “announc[ing] receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the 505(b)(2) New Drug Application (NDA) of ADX-2191 (methotrexate for injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma (PVRL).” The press release state that “[a]lthough no safety or manufacturing issues with ADX-2191 were identified, the FDA stated that there was a ‘lack of substantial evidence of effectiveness’ due to ‘a lack of adequate and well-controlled investigations’ in the literature-based NDA submission.” On his news, Aldeyra’s stock price fell $2.92 per share, or 27.44%, to close at $7.72 per share on June 21, 2023. The complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the ADX-2191 NDA did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191’s effectiveness; (ii) as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form; (iii) accordingly, the company had overstated ADX-2191’s clinical and/or commercial prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times. If you purchased or otherwise acquired Aldeyra shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you. About Bragar Eagel & Squire, P.C. : Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. View source version on businesswire.com: https://www.businesswire.com/news/home/20230807253809/en/ Share
Aldeyra疗法常见问题(FAQ)
Aldeyra疗法的总部在哪里?
Aldeyra疗法的总部位于哈特韦尔大道131,列克星敦。
Aldeyra疗法的最新一轮融资是什么?
Aldeyra疗法的最新一轮融资是上市。
Aldeyra疗法筹集了多少钱?
Aldeyra疗法提出总计15.26美元。
Aldeyra疗法的投资者是谁?
Aldeyra疗法的投资者包括域Associates强生BridgeGap企业创新和访问。
Aldeyra疗法的竞争对手是谁?
竞争对手Aldeyra疗法包括Lubris生物制药。
竞争对手比较Aldeyra疗法
Biosplice疗法是一种临床分期生物科技公司开拓基于替代pre-mRNA拼接重大疾病的疗法。其科学平台是基于生物发现管理组织专业化和使它使用小分子选择性地消除有害的蛋白质。从公司的基本发现Wnt通路调制解锁的广泛的治疗潜力CLK / DYRK目标类,其重点是实现新的、潜在的治疗治疗患者通过选择性地重新编程细胞行为。
Lubris生物制药是一家生物制药公司。发展重组人类lubricin治疗干眼病,骨关节炎,手术粘连,口腔干燥,心包炎。它成立于2011年,总部设在韦斯顿,马萨诸塞州。
牡蛎点制药公司(纳斯达克:OYST)是一种临床分期制药公司。它着重于发现、开发和商业化的疗法来治疗疾病高未满足的需求。公司的初始焦点是开发治疗治疗干眼疾病的症状和体征(d)通过刺激三叉神经副交感神经通路激活腺体负责催泪电影制作。公司成立于2015年,位于普林斯顿,新泽西。2023年1月,牡蛎制药被Viatris收购。
Bioventus(纳斯达克:bv)是一种orthobiologics公司提供临床证明,具有成本效益的产品,帮助人们治愈快速和安全。orthobiologics的公司有两个产品组合,Bioventus积极的康复治疗和Bioventus手术,使它成为一个全球领先的活跃的骨科治疗。